CX Institutional’s BioMarin Pharmaceuticals BMRN Stock Holding History

CX Institutional’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13K	Sell	234 -54	-19%	-$2.96K	﹤0.01%	1249
2026 Q1	$16K	Buy	288 +260	+929%	+$15.2K	﹤0.01%	1176
2025 Q4	$2K	Buy	+28	New	+$1.52K	﹤0.01%	1351
2021 Q4	–	Sell	-10	Closed	-$1K	–	399
2021 Q3	$1K	Hold	10	–	–	﹤0.01%	930
2021 Q2	$1K	Buy	+10	New	+$793	﹤0.01%	929
2021 Q1	–	Sell	-17	Closed	-$1K	–	870
2020 Q4	$1K	Sell	17 -3	-15%	-$238	﹤0.01%	841
2020 Q3	$2K	Buy	+20	New	+$2.02K	﹤0.01%	800
2019 Q3	–	Sell	-27	Closed	-$2K	–	805
2019 Q2	$2K	Sell	27 -24	-47%	-$2.05K	﹤0.01%	743
2019 Q1	$5K	Buy	+51	New	+$4.73K	﹤0.01%	539

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

CX Institutional's BMRN Position: Q2 2026 in Review

CX Institutional reduced its BioMarin Pharmaceuticals (BMRN) stake by 19% in Q2 2026, selling an estimated $2.96K and leaving 234 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #1249.

CX Institutional first reported a position in BMRN in Q1 2019 and has held it in 9 quarters since. The position peaked at $16K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

CX Institutional held 234 shares of BioMarin Pharmaceuticals worth $13K as of Q2 2026.
CX Institutional sold 54 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.96K.
BioMarin Pharmaceuticals made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #1249 holding.
CX Institutional first reported a position in BioMarin Pharmaceuticals in Q1 2019 and has held it in 9 quarters since.
CX Institutional's BioMarin Pharmaceuticals position peaked at $16K in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.